What is the real market size of the longevity market?
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market is one of the most exciting sectors emerging in healthcare and biotech today.
Investment in longevity startups more than doubled in 2024, reaching $8.49 billion across 331 deals.
This surge signals that extending healthy human lifespan is no longer science fiction but a serious business opportunity.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Japan approved NMN as a functional food in late 2024, and now 7.2 million Japanese regularly consume NMN products, making it a leading longevity supplement market.
- The FDA does not recognize aging as a disease, which means longevity drugs cannot be approved for "treating aging" until the TAME Trial potentially changes this.
- Altos Labs raised over $5.5 billion in total funding, making it the most well-funded longevity biotech company in history, backed by Jeff Bezos and Yuri Milner.
- Unity Biotechnology lost 99% of its value, dropping from nearly $300 million valuation to under $4 million, serving as a cautionary tale for pure-play senolytic investors.
- Oura Ring reached an $11 billion valuation in October 2025 after selling 5.5 million units and generating over $500 million in annual revenue from longevity tracking.
- China produces 70% of the world's NMN supply and captures 70% of global NMN health supplement revenue, dominating this key longevity ingredient market.
- Forward Health raised $650 million but shut down in 2024, highlighting that customer acquisition costs can kill even well-funded longevity consumer startups.
- Four FDA-approved drugs already show longevity benefits: SGLT2 inhibitors, metformin, bisphosphonates, and GLP-1 agonists, enabling off-label prescriptions today.
- Longevity clinics are growing headcount by 37% year-over-year, the fastest growth rate of any category in the longevity market.
- TruDiagnostic built the largest private epigenetic database with 75,000+ patients tested, creating a valuable data moat in biological age testing.
How do we define the longevity market?
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
We also use this definition when we make and update our pitch covering everything there is to know about the longevity market.
In our longevity market deck, we will give you useful market maps and grids
What is the size of the longevity market in 2026?
What results can we find on the internet?
As you probably know already, many firms regularly publish (sometimes conflicting) estimates of the longevity market size, using different definitions, scopes, and years.
We have consolidated their results here. We will use it, among other things, to derive a single, reasonable estimate of the market size.
| Source | Market Size (USD) | Year | Scope and Notes |
|---|---|---|---|
| Emergen Research | $27.1B | 2024 | Includes supplements, life extension therapies, diagnostics, wearables, and regenerative medicine. This aligns closely with our definition of the longevity market. |
| Cognitive Market Research | $27.15B | 2024 | Focuses on senolytic drugs, gene therapy, immunotherapy, and stem cell therapy. This is narrower than our definition because it excludes supplements and clinics. |
| Business Research Insights | $28.91B | 2024 | Covers gene therapy and cell therapies for longevity. This is narrower because it focuses mainly on therapeutics rather than the full longevity ecosystem. |
| Market Research Future | $21.29B | 2024 | Includes health and wellness services, nutraceuticals, life extension therapies, and genetic testing. This matches our definition well but sits on the lower end of estimates. |
| Verified Market Research | $18.6B | 2024 | Focuses on pharmaceuticals and supplements only. This is narrower than our definition because it excludes clinics, diagnostics, and digital tools. |
| Grand View Research | $4.13B | 2024 | Covers senolytics and anti-aging pharmaceuticals only. This is much narrower than our definition and represents just the drug development segment. |
What can we conclude, then?
The estimates that best match our definition cluster between $21 billion and $29 billion for 2024, with most landing around $27 billion.
The lower estimates (like Grand View's $4 billion) focus only on pharmaceuticals, while our definition includes supplements, clinics, diagnostics, and digital tools.
For our first estimate, we take the $25 billion midpoint for 2024 and grow it by 8% annually, giving us approximately $29 billion for the longevity market in 2026.
In our longevity market deck, we have collected signals proving this market is hot right now
What if we try to make our own estimate?
We don't have to rely only on external analyses to estimate market size.
We will try to build a first-principles, bottom-up calculation, then run a few sanity checks to see whether we can reliably estimate the size of the longevity market.
Useful data about the longevity market
Here is some useful and reliable data we have collected, they will help us estimate the size of the longevity market:
- ChromaDex (Tru Niagen) generated $99.6 million in revenue in 2024 (ChromaDex Investor Relations)
- The global NAD+ products market reached $3.45 billion in 2024 (Grand View Research)
- Oura Ring generated over $500 million in revenue in 2024 (Business Wire)
- There are approximately 800 longevity clinics operating in the United States (A4M)
- Fountain Life membership costs $21,500 per year (Health Club Management)
- TruDiagnostic has tested over 75,000 patients for biological age (TruDiagnostic)
- Longevity startup investment reached $8.49 billion across 331 deals in 2024 (PR Newswire)
- Japan has 7.2 million regular NMN consumers after functional food approval (Business Research Insights)
- The senolytics and anti-aging pharmaceuticals market reached $4.13 billion in 2024 (Grand View Research)
- Supplements hold approximately 42% market share of the longevity market (Emergen Research)
Method and calculation to get the size of the longevity market
Let's build up from the major segments. We know supplements represent about 42% of the longevity market.
The NAD+ market alone is $3.45 billion. Add CoQ10 ($700 million), resveratrol ($200 million), spermidine ($175 million), and other longevity supplements.
This gives us roughly $6 to $8 billion in longevity supplements for 2024. If that's 42% of the market, the total would be $14 to $19 billion.
But this feels low. Let's cross-check with clinics and services.
With 800 US longevity clinics and premium memberships around $20,000 per year, even 5,000 members per clinic generates $80 billion. That seems too high, so average revenue per clinic must be much lower.
More realistically, if the average longevity clinic generates $2 to $5 million annually, the US clinic market is $1.6 to $4 billion. Globally, this could reach $4 to $6 billion.
Adding Oura Ring ($500 million), other wearables, and diagnostics brings another $2 to $3 billion.
Pharmaceuticals and therapeutics in development add approximately $4 billion in current revenue.
Our bottom-up calculation suggests $16 to $21 billion for 2024. Growing this by 8% annually brings us to $19 to $25 billion for 2026.
Sanity checks
Let's verify this estimate makes sense. The $8.49 billion invested in longevity startups in 2024 represents about 30% to 40% of total market revenue.
This ratio is typical for high-growth sectors where investors bet on future growth. It suggests our market size is in the right ballpark.
Another check: Oura Ring alone generated $500 million. For one company to represent 2% of a market is reasonable for a category leader.
If Oura were 2% of the market, that implies a $25 billion total. This aligns well with our estimates.
Finally, the longevity market should be smaller than the broader anti-aging market ($77 billion), which includes cosmetics and beauty. Our $25 to $30 billion estimate fits this constraint.
What's our final guess then?
After reviewing external estimates and building our own bottom-up calculation, we believe the longevity market is worth approximately $28 to $30 billion in 2026.
This represents roughly 8% annual growth from the 2024 baseline of $25 billion.
For comparison, the global smart ring market is about $1 billion, the probiotics market is $60 billion, and the dietary supplements market is $180 billion.
The longevity market sits comfortably between niche health tech and mass-market supplements. This positioning makes sense given its focus on scientifically-backed interventions.
Our best estimate for the longevity market in 2026 is $29 billion, with a reasonable range of $27 to $32 billion depending on how quickly therapeutics advance.
In our longevity market deck, we provide the data and the context to understand it
Is the longevity market mature, competitive, fragmented?
The maturity score of the longevity market in 2026 is 25/100
The longevity market is still in its early stages. The FDA does not recognize aging as a disease, which means no drug has ever been approved specifically for longevity.
Most revenue comes from supplements and wellness services rather than proven therapeutics. Only four FDA-approved drugs show longevity benefits, and none were developed for that purpose.
The TAME Trial could change everything by establishing aging as an approved indication. Until then, the longevity market remains pre-regulatory and immature.
The competitiveness score of the longevity market in 2026 is 55/100
Competition is heating up rapidly. Investment more than doubled in 2024 to $8.49 billion, attracting major players like Alphabet (Calico), Jeff Bezos (Altos Labs), and Sam Altman (Retro Biosciences).
However, high barriers exist in therapeutics. Drug development takes 10 to 15 years and costs over $1 billion, limiting competition to well-funded players.
In supplements and consumer products, competition is fierce. Low barriers to entry mean thousands of companies compete on marketing rather than science.
The fragmentation score of the longevity market in 2026 is 75/100
The longevity market is highly fragmented. There are over 3,200 longevity startups globally, with no single company holding more than 5% market share.
Five distinct segments exist: supplements, therapeutics, clinics, diagnostics, and digital tools. Leaders in one segment rarely compete in others.
This fragmentation creates opportunity for consolidation. Altos Labs acquiring Dorian Therapeutics in 2025 signals that larger players are starting to roll up the market.
How much bigger will the longevity market be in 10 years?
What are the different forecasts for the growth rate of the longevity market?
One more time, let's check what other market research firms have to say.
| Source | Annual Growth Rate | Until Year | Comments and Adjustments |
|---|---|---|---|
| Market Research Future | 10.37% | 2035 | This covers health services, therapies, and nutraceuticals. The definition matches ours well. We can use this estimate directly without major adjustments. |
| Emergen Research | 9.0% | 2034 | Includes supplements, diagnostics, and therapies. This aligns with our definition. The 9% rate seems reasonable for sustained growth. |
| Cognitive Market Research | 6.5% | 2031 | Focuses only on therapies, excluding supplements and clinics. This is conservative and narrower. We should adjust upward for the full market. |
| Business Research Insights | 6.5% | 2033 | Covers gene and cell therapies only. This narrow scope explains the lower growth rate. Consumer segments grow faster than therapeutics alone. |
| Verified Market Research | 14.7% | 2030 | Covers pharmaceuticals and supplements. This high rate may reflect optimism about drug approvals. We should treat this as an upper bound. |
| Grand View Research | 7.59% | 2030 | Focuses on senolytics and pharmaceuticals only. This is narrower than our definition. Pharmaceutical-only growth tends to be slower than consumer products. |
What can we conclude about the growth rate of the longevity market?
Most estimates cluster between 6.5% and 10% annual growth. The outlier at 14.7% assumes major drug approvals that may not materialize.
We believe 8% annual growth is the most realistic baseline for the longevity market. This balances strong consumer demand with regulatory uncertainty in therapeutics.
At 8% growth, the longevity market would reach approximately $43 billion by 2030. That is roughly 1.5 times larger than today.
By 2036, the longevity market would grow to approximately $68 billion. That is about 2.3 times larger than 2026.
This growth rate is similar to the broader health and wellness sector. It is faster than traditional pharmaceuticals but slower than digital health.
If the TAME Trial succeeds in making aging an FDA-approved indication, growth could accelerate to 12% or higher. This would push the 2036 market size above $90 billion.
For now, we project the longevity market will grow at 8% annually, reaching $43 billion by 2030 and $68 billion by 2036.
And if you're curious about what's happening in this (really interesting) market, we publish a quarterly update on the activity in the longevity market here. We also have a monthly update here.
In our longevity market deck, we dentify risks investors and builders need to be aware of
What is the projected CAGR for the longevity market?
At New Market Pitch, we like it when the information is clear and easy to digest, as you will see in the pitch about the longevity market. That's also why we have made this clear summary table.
| Year | Worst Case (5% annual growth rate) | Realistic (8% annual growth rate) | Best Case (12% annual growth rate) |
|---|---|---|---|
| 2027 | $30.5B | $31.3B | $32.5B |
| 2028 | $32.0B | $33.8B | $36.4B |
| 2029 | $33.6B | $36.5B | $40.8B |
| 2030 | $35.3B | $39.4B | $45.7B |
| 2031 | $37.1B | $42.6B | $51.2B |
| 2032 | $38.9B | $46.0B | $57.3B |
| 2033 | $40.9B | $49.7B | $64.2B |
| 2034 | $42.9B | $53.6B | $71.9B |
| 2035 | $45.1B | $57.9B | $80.5B |
| 2036 | $47.3B | $62.6B | $90.2B |
What would it take for the longevity market to be worth $100 billion?
For the longevity market to reach $100 billion by 2036, annual growth would need to exceed 13%. That requires several major breakthroughs happening together.
First, the FDA would need to recognize aging as a treatable condition. The TAME Trial results, expected in the late 2020s, could establish this precedent.
Second, at least two or three senolytic drugs would need to reach Phase 3 trials with positive results. Currently, 23 senolytic compounds are in development, but none have advanced past Phase 2.
Third, insurance coverage for longevity interventions would need to expand significantly. Today, most longevity treatments are paid out of pocket, limiting the addressable market.
Fourth, Asia would need to accelerate adoption faster than projected. China already dominates NMN production, and Japan has 7.2 million regular consumers.
Fifth, a major tech company would need to commercialize a breakthrough. The Retro Biosciences and OpenAI partnership hints at this possibility with their 50x improvement in cell reprogramming.
Reaching $100 billion is possible but requires multiple catalysts. Our base case projects $63 billion, with $90 billion achievable under optimistic assumptions.
In our longevity market deck, we answer all the common questions from investors and entrepreneurs
Where is the money in the longevity market?
What are the categories and how much do they generate?
Supplements dominate the longevity market with approximately 42% of revenue in 2026. This includes NAD+ boosters, NMN, resveratrol, and other anti-aging compounds.
Therapeutics and pharmaceuticals represent about 25% of the market. This segment includes senolytics, gene therapy, and immunotherapy products in development or early commercialization.
Clinics and services account for roughly 22% of revenue. Premium longevity clinics like Fountain Life charge $21,500 per year for membership.
Diagnostics capture approximately 6% of the market. Biological age testing from companies like TruDiagnostic costs around $500 per test.
Digital tools and wearables make up the remaining 5%. Oura Ring leads this category with over $500 million in annual revenue.
Finally, if you really want to understand where is the money, you can check our ranking of the most funded startups in the longevity market as well as our list of the most valued startups.
How will it evolve?
By 2030, therapeutics will likely grow to 30% of the longevity market as more drugs enter late-stage trials. Supplements may decline to 38% as consumers shift toward proven interventions.
Diagnostics will expand to 10% by 2030. Biological age testing is becoming more affordable and mainstream.
By 2036, therapeutics could reach 35% of the longevity market if several drugs gain approval. This would be the most dramatic category shift.
Clinics will likely hold steady at 20% to 22%. The high-touch service model limits scalability.
Digital tools may grow to 8% by 2036 as AI-powered health monitoring becomes standard. Wearables are increasingly integrated with longevity protocols.
Where to spend your energy as an investor or a builder in the longevity market then?
For investors seeking near-term returns, diagnostics offer the best risk-reward profile. Companies like TruDiagnostic reached market in two to three years with CLIA certification.
Therapeutics offer the highest potential returns but require patient capital. Altos Labs' $7 billion valuation shows what success looks like, but Unity Biotechnology's 99% collapse shows the downside.
For builders, the clinic segment has proven unit economics. Midi Health projects $150 million revenue in 2025, up from $60 million in 2024.
Supplements are crowded but still profitable. ChromaDex generated $100 million in 2024 from Tru Niagen alone. Differentiation requires clinical evidence and patented ingredients.
The emerging opportunity is AI-powered longevity platforms. Discovery platforms raised $2.65 billion in 2024, representing 28% of total longevity investment.
And if you're curious about where investors are putting their money right now, we publish a quarterly update on the fundraising activity in the longevity market here. We also analyze long-term funding trends in the longevity market here.
In our longevity market deck, we track adoption trends and shifts in consumer behavior
What is the geographical revenue breakdown for the longevity market?
North America
North America holds approximately 42% of the longevity market in 2026, generating around $12 billion in revenue. The United States accounts for 85% of this total.
The US dominates because it hosts 8,500 clinical centers and biotech firms working on anti-aging research. California, New York, and Florida are the largest state markets.
By 2030, North America's share may decline slightly to 40% as Asia-Pacific grows faster. The absolute market will still reach approximately $17 billion.
By 2036, North America will likely hold 38% of the longevity market. The region will remain the center of therapeutics development and clinical research.
Europe
Europe represents approximately 28% of the longevity market in 2026, worth about $8 billion. Germany, UK, France, and Switzerland lead in longevity spending.
Switzerland hosts premium destination clinics like Clinique La Prairie, where treatments start at $53,000 per week. 52% of European health institutions have integrated regenerative medicine programs.
By 2030, Europe will likely maintain its 28% share. The region prefers non-invasive therapies, with 46% of consumers choosing these options.
By 2036, Europe may slip to 26% as Asia-Pacific expands. However, strong regulatory frameworks will continue to attract high-value therapeutics development.
Asia-Pacific
Asia-Pacific holds approximately 22% of the longevity market in 2026, generating around $6.4 billion. China accounts for 40% of this regional total.
China produces 70% of global NMN supply and captures 70% of NMN supplement revenue. Japan approved NMN as a functional food in late 2024, creating 7.2 million regular consumers.
By 2030, Asia-Pacific will likely grow to 26% of the longevity market. The region's 8% to 10% annual growth rate outpaces other regions.
By 2036, Asia-Pacific could reach 30% of the global longevity market. South Korea's 51% surge in NMN consumption in 2024 signals continued regional momentum.
Rest of World
The Middle East, Africa, and Latin America together represent approximately 8% of the longevity market in 2026, worth about $2.3 billion.
The UAE and Saudi Arabia are investing heavily in longevity infrastructure. Israel contributes significant biotech innovation to the longevity sector.
By 2030, these regions will likely grow to 9% of the market. Wealthy individuals in emerging markets increasingly seek premium longevity services.
By 2036, rest of world could reach 10% of the longevity market as healthcare infrastructure improves and disposable income rises.
In our longevity market deck, we have designed useful charts to give you full market clarity
What other interesting data are there regarding the longevity market?
For investors in the longevity market
- A 2021 Nature Aging study estimated global willingness to pay at $38 trillion for one additional year of healthy life, rising to $367 trillion for ten years (Nature Aging)
- Later-stage venture capital comprised 31% of total longevity funding in 2024, up significantly from prior years, signaling the sector is maturing beyond early speculation (Longevity Technology)
- BioAge Labs completed a $238 million IPO in September 2024 at $18 per share, becoming the largest longevity-focused public offering of the year (Stock Titan)
- The US captures 84% of global longevity investment deal flow, making it the clear center of gravity for longevity capital allocation (PR Newswire)
- Major institutional investors now active in longevity include Khosla Ventures, Andreessen Horowitz, ARCH Venture Partners, and pharma venture arms from Eli Lilly and Amgen (Quick Market Pitch)
- AbbVie ended its 11-year partnership with Calico Labs after investing over $1.5 billion, following a failed ALS drug trial (Longevity Technology)
For builders in the longevity market
- Longevity clinics are growing headcount by 37% year-over-year, the fastest growth of any category, with Neko Health maintaining a 100,000+ person waitlist (CB Insights)
- Loyal has raised over $125 million developing longevity drugs for dogs, with FDA conditional approval expected in 2025, potentially providing proof-of-concept data for human trials (Gov Capital)
- The Retro Biosciences and OpenAI partnership developed GPT-4b micro for protein engineering, achieving a 50x boost in cell reprogramming efficiency (CB Insights)
- Consumer biological age tests typically price between $400 and $500 per test, with subscription models offering $998 per year for multiple annual tests (My Nucleus)
- 47% of NMN supplement purchases occur via direct-to-consumer subscriptions, with over 40% of users aged 45 and above (Business Research Insights)
- Forward Health raised $650 million but shut down in 2024, demonstrating that high customer acquisition costs can sink even well-funded longevity consumer startups (Longevity Foundation)
- Insilico Medicine signed a $1.2 billion collaboration with Sanofi for AI drug discovery, showing pharmaceutical giants are eager to partner with longevity-focused AI platforms (Longevity Technology)
In our longevity market deck, we focus on making things as clear as possible
Related blog posts
- The most recent news in the longevity market
- The most highly valued startups in the longevity market
- The latest developments shaping the longevity market
- The evolution of funding activity in the longevity market
- The main fundraising trends in the longevity market
- The startups that have raised the most funding in the longevity market
